Retrospective analysis of patient flow in NSCLC with delayed detection of druggable mutation using C-CAT database

JRCT ID: jRCT1030230246

Registered date:20/07/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: NSCLC
• Date of first enrollment: 20/07/2023
• Target sample size: 1314
• Study type: Other

Outcome(s)

Primary Outcome

Among patients with NSCLC diagnosed with wild type (WT) who have completed (or are expected to complete) standard therapy and who underwent comprehensive genomic profiling (CGP) testing, the proportion of patients diagnosed with a drug-treatable mutation by CGP testing ratio
Among patients with NSCLC diagnosed with WT who have completed (or are expected to complete) standard therapy and who underwent comprehensive genomic profiling (CGP) testing, the proportion of patients diagnosed with a drug-treatable mutation by CGP testing , percentage by year

Secondary Outcome

Describe the characteristics of NSCLC patients with delayed detection of drug-treatable genetic mutations
Describe the degree of delay in NSCLC patients with delayed detection of drug-treatable genetic mutations
Describe treatment patterns for NSCLC patients with delayed detection of drug-treatable genetic mutations
Describe the frequency of delayed detection of drug-treatable genetic mutations by site type

Patient baseline characteristics (gender, age, family history, etc.)
Time from start of first-line therapy to detection of a drug-treatable mutation
Treatment patterns for NSCLC patients with drug-treatable mutations
Number and proportion of regimens in each line of treatment
Duration of each line of therapy
Percentage of patients diagnosed with a drug-treatable mutation by CGP testing, by facility type (size, academic/community, etc.)

Key inclusion & exclusion criteria

• Age minimum: >= 15age old
• Age maximum: Not applicable
• Include criteria: Adult (aged 15 years or more) patients with histologically or cytologically confirmed NSCLC

Exclude criteria

1. Patients who have already been confirmed to have a drug-treatable mutation/translocation by the end of standard therapy
2. Patients who received targeted therapy against driver genes before finishing standard therapy

Related Information

• Primary Sponsor: Yokochi Yuya